Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 20 | 2019 | 226 | 4.140 |
Why?
|
| Cognition | 17 | 2019 | 526 | 2.150 |
Why?
|
| Aging | 9 | 2016 | 881 | 2.020 |
Why?
|
| Estrogen Replacement Therapy | 15 | 2017 | 182 | 1.690 |
Why?
|
| Estrogens, Conjugated (USP) | 12 | 2017 | 125 | 1.650 |
Why?
|
| Postmenopause | 19 | 2019 | 397 | 1.370 |
Why?
|
| Quality of Life | 13 | 2016 | 816 | 1.210 |
Why?
|
| Cognition Disorders | 11 | 2019 | 390 | 1.190 |
Why?
|
| Hormone Replacement Therapy | 6 | 2019 | 86 | 1.070 |
Why?
|
| Disability Evaluation | 2 | 2016 | 211 | 1.020 |
Why?
|
| Activities of Daily Living | 6 | 2016 | 240 | 1.010 |
Why?
|
| Dementia | 7 | 2019 | 234 | 0.960 |
Why?
|
| Geriatric Assessment | 2 | 2016 | 355 | 0.950 |
Why?
|
| Medroxyprogesterone Acetate | 8 | 2017 | 89 | 0.870 |
Why?
|
| Female | 49 | 2019 | 18173 | 0.840 |
Why?
|
| Memory | 6 | 2017 | 187 | 0.780 |
Why?
|
| Health Status | 11 | 2016 | 368 | 0.760 |
Why?
|
| Humans | 56 | 2019 | 29123 | 0.700 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2005 | 48 | 0.700 |
Why?
|
| Diabetic Neuropathies | 1 | 2019 | 23 | 0.690 |
Why?
|
| Aged | 39 | 2019 | 9492 | 0.660 |
Why?
|
| Affect | 3 | 2018 | 63 | 0.660 |
Why?
|
| Neuralgia | 1 | 2019 | 48 | 0.660 |
Why?
|
| Aged, 80 and over | 13 | 2019 | 3719 | 0.650 |
Why?
|
| United States | 14 | 2018 | 3632 | 0.580 |
Why?
|
| Motor Activity | 3 | 2016 | 310 | 0.560 |
Why?
|
| Neuropsychological Tests | 11 | 2019 | 379 | 0.560 |
Why?
|
| Polysomnography | 1 | 2016 | 33 | 0.560 |
Why?
|
| Tamoxifen | 3 | 2012 | 48 | 0.550 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 47 | 0.540 |
Why?
|
| Independent Living | 1 | 2016 | 78 | 0.540 |
Why?
|
| Patient Dropouts | 1 | 2015 | 24 | 0.520 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1379 | 0.500 |
Why?
|
| Geriatrics | 1 | 2015 | 94 | 0.490 |
Why?
|
| Patient Compliance | 1 | 2015 | 208 | 0.460 |
Why?
|
| Depression | 6 | 2012 | 382 | 0.460 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 1017 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 464 | 0.450 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2010 | 29 | 0.450 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 10 | 0.440 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 26 | 0.430 |
Why?
|
| Schizophrenia | 1 | 2012 | 38 | 0.430 |
Why?
|
| Middle Aged | 27 | 2019 | 10834 | 0.420 |
Why?
|
| Adaptation, Psychological | 3 | 2019 | 125 | 0.420 |
Why?
|
| Estrogens | 6 | 2013 | 162 | 0.400 |
Why?
|
| Medroxyprogesterone | 2 | 2017 | 12 | 0.400 |
Why?
|
| Women's Health Services | 2 | 2013 | 9 | 0.400 |
Why?
|
| Breast Neoplasms | 4 | 2012 | 666 | 0.400 |
Why?
|
| Health Surveys | 3 | 2016 | 191 | 0.390 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 150 | 0.380 |
Why?
|
| Progesterone Congeners | 3 | 2006 | 15 | 0.360 |
Why?
|
| Cohort Studies | 5 | 2016 | 1688 | 0.310 |
Why?
|
| Risk Factors | 10 | 2019 | 3537 | 0.300 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 709 | 0.290 |
Why?
|
| Memory Disorders | 2 | 2017 | 61 | 0.280 |
Why?
|
| Training Support | 1 | 2006 | 5 | 0.280 |
Why?
|
| Research Support as Topic | 1 | 2006 | 25 | 0.280 |
Why?
|
| Incidence | 5 | 2019 | 1119 | 0.270 |
Why?
|
| Double-Blind Method | 8 | 2019 | 503 | 0.270 |
Why?
|
| Faculty, Medical | 1 | 2006 | 69 | 0.260 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 92 | 0.260 |
Why?
|
| Psychometrics | 4 | 2012 | 129 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 92 | 0.240 |
Why?
|
| Factor Analysis, Statistical | 3 | 2012 | 70 | 0.230 |
Why?
|
| Sickness Impact Profile | 1 | 2003 | 34 | 0.220 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 726 | 0.220 |
Why?
|
| Health Services Research | 1 | 2003 | 78 | 0.210 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 298 | 0.200 |
Why?
|
| Finasteride | 2 | 2012 | 12 | 0.190 |
Why?
|
| Cause of Death | 2 | 2018 | 220 | 0.190 |
Why?
|
| Self Care | 2 | 2016 | 137 | 0.180 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.180 |
Why?
|
| Dietary Supplements | 2 | 2019 | 170 | 0.180 |
Why?
|
| Risk | 5 | 2017 | 289 | 0.180 |
Why?
|
| Treatment Outcome | 8 | 2017 | 3101 | 0.180 |
Why?
|
| Vitamins | 1 | 2019 | 59 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2019 | 60 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2019 | 142 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2018 | 440 | 0.160 |
Why?
|
| Alzheimer Disease | 2 | 2019 | 312 | 0.160 |
Why?
|
| Depressive Disorder | 1 | 2018 | 74 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2018 | 1306 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 787 | 0.150 |
Why?
|
| Androgens | 1 | 2017 | 22 | 0.150 |
Why?
|
| Particulate Matter | 1 | 2017 | 30 | 0.150 |
Why?
|
| Testosterone | 1 | 2017 | 47 | 0.150 |
Why?
|
| Mortality | 1 | 2017 | 109 | 0.150 |
Why?
|
| Caffeine | 1 | 2016 | 31 | 0.140 |
Why?
|
| Placebos | 3 | 2007 | 61 | 0.140 |
Why?
|
| Age Factors | 3 | 2005 | 1108 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2017 | 87 | 0.140 |
Why?
|
| Decision Making, Organizational | 1 | 2016 | 4 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1219 | 0.140 |
Why?
|
| Oximetry | 1 | 2016 | 28 | 0.140 |
Why?
|
| Ethnic Groups | 3 | 2018 | 440 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 53 | 0.140 |
Why?
|
| Male | 9 | 2019 | 17815 | 0.130 |
Why?
|
| Automobile Driving | 1 | 2015 | 24 | 0.130 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 441 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 836 | 0.130 |
Why?
|
| Life Style | 2 | 2016 | 364 | 0.130 |
Why?
|
| Burnout, Professional | 1 | 2016 | 44 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2016 | 263 | 0.130 |
Why?
|
| Demography | 1 | 2015 | 104 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 24 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2015 | 67 | 0.130 |
Why?
|
| Adult | 5 | 2012 | 8426 | 0.130 |
Why?
|
| Research Design | 4 | 2004 | 286 | 0.130 |
Why?
|
| Progestins | 2 | 2005 | 18 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 153 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2013 | 37 | 0.120 |
Why?
|
| Sampling Studies | 2 | 2003 | 40 | 0.120 |
Why?
|
| Refusal to Participate | 1 | 2013 | 4 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2003 | 119 | 0.110 |
Why?
|
| Heart Failure | 1 | 2018 | 571 | 0.110 |
Why?
|
| Telephone | 1 | 2012 | 48 | 0.110 |
Why?
|
| Focus Groups | 1 | 2012 | 103 | 0.110 |
Why?
|
| Longitudinal Studies | 5 | 2018 | 721 | 0.100 |
Why?
|
| Patient Selection | 1 | 2013 | 257 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 863 | 0.100 |
Why?
|
| Learning | 1 | 2011 | 76 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2012 | 144 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 20 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 23 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 546 | 0.080 |
Why?
|
| Hot Flashes | 2 | 2005 | 46 | 0.080 |
Why?
|
| Vitamin D | 1 | 2008 | 172 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 48 | 0.070 |
Why?
|
| Brain | 1 | 2014 | 930 | 0.070 |
Why?
|
| North Carolina | 2 | 2012 | 1423 | 0.070 |
Why?
|
| Financing, Organized | 1 | 2006 | 14 | 0.070 |
Why?
|
| Budgets | 1 | 2006 | 10 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2012 | 2021 | 0.070 |
Why?
|
| Benchmarking | 1 | 2006 | 25 | 0.070 |
Why?
|
| Schools, Medical | 1 | 2006 | 42 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2006 | 175 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2005 | 3 | 0.070 |
Why?
|
| Norethindrone | 1 | 2005 | 1 | 0.070 |
Why?
|
| Drug Industry | 1 | 2005 | 14 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 29 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 44 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 80 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 2109 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 107 | 0.060 |
Why?
|
| Estradiol | 1 | 2005 | 118 | 0.060 |
Why?
|
| Menopause | 1 | 2005 | 86 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 162 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 1362 | 0.060 |
Why?
|
| Linear Models | 3 | 2012 | 426 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2005 | 229 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 100 | 0.060 |
Why?
|
| Physicians | 1 | 2005 | 134 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2003 | 200 | 0.050 |
Why?
|
| Continental Population Groups | 2 | 2018 | 221 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 360 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 34 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2002 | 260 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 36 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 72 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 97 | 0.040 |
Why?
|
| Mental Health | 2 | 2012 | 104 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 391 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2001 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cerebrum | 1 | 2017 | 6 | 0.040 |
Why?
|
| Neurites | 1 | 2017 | 8 | 0.040 |
Why?
|
| Gels | 1 | 2017 | 33 | 0.040 |
Why?
|
| Receptors, AMPA | 1 | 2017 | 14 | 0.040 |
Why?
|
| Atrophy | 1 | 2017 | 51 | 0.040 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2017 | 26 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 518 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 54 | 0.040 |
Why?
|
| Mental Recall | 1 | 2017 | 52 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 58 | 0.040 |
Why?
|
| Reference Values | 1 | 2017 | 224 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 249 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 2016 | 6 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 22 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 26 | 0.030 |
Why?
|
| African Americans | 2 | 2018 | 1373 | 0.030 |
Why?
|
| Proxy | 1 | 2015 | 9 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 33 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1079 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 681 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 106 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 196 | 0.030 |
Why?
|
| Research Subjects | 1 | 2013 | 28 | 0.030 |
Why?
|
| Social Support | 2 | 2003 | 163 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2003 | 274 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 447 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2012 | 163 | 0.030 |
Why?
|
| Neoplasms | 1 | 2017 | 611 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 165 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2370 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 727 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 469 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 2 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2008 | 149 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 162 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7299 | 0.020 |
Why?
|
| Progesterone | 1 | 2004 | 80 | 0.010 |
Why?
|
| Income | 1 | 2003 | 52 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2004 | 70 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 61 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 163 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 45 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 159 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2003 | 97 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 641 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 631 | 0.010 |
Why?
|
| Health Behavior | 1 | 2003 | 214 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 898 | 0.010 |
Why?
|
| Exercise | 1 | 2004 | 592 | 0.010 |
Why?
|